Documents to download

In 2019, the provision of Pre-exposure Prophylaxis (PrEP), an anti-HIV medication, has continued to attract attention. PrEP is a drug taken by HIV-negative individuals at risk of acquiring HIV, which reduces viral replication and minimises the chance of a permanent infection developing.

Although PrEP is widely available in Scotland, access in England has initially been through an impact trial. The Terrence Higgins Trust has campaigned for PrEP to be made available through routine commissioning in all parts of the country. It states that while it is “achievable” to “end HIV transmission in the UK”, this can only happen if “we use all of the tools available to us”, including PrEP. On 29 October 2019, the Secretary of State for Health and Social Care, Matt Hancock, said that the “roll-out from a trial to routine commissioning will happen in April (2020)”. However, various campaigners remain concerned that people will contract HIV while waiting to access the medication.

The key PrEP developments since 2016 have been:

  • In December 2016, NHS England committed to a large-scale PrEP trial, which aimed to establish the demand for PrEP and how long people stay on the treatment in a real-world setting.
  • In October 2017, the impact trial was launched with 10,000 places. This was increased to 13,000 in June 2018 to adjust for the initial high recruitment. In early 2019, NHS England’s Programme Oversight Board agreed to expand the trial to include 26,000 participants.
  • In October 2019, NHS England provided an update that 15,700 people across 153 clinics had received PrEP through the trial. Almost all trial clinics are now open and recruiting with thousands of places on the trial remaining available across all eligible at-risk groups and geographies.

The Department of Health and Social Care has stated that it will work with local authorities in England to plan for a “seamless transition” from the trial to routine commissioning in 2020/21.


Documents to download

Related posts

  • Smoke-free legislation: The UK and New Zealand

    During the 2023–24 session, the UK government introduced legislation to raise the age each year at which someone can legally buy tobacco products. This was similar to measures introduced in New Zealand which were recently reversed. This briefing looks at developments in New Zealand and how they have informed the debate on the UK government’s proposals.

    Smoke-free legislation: The UK and New Zealand
  • Infected blood scandal: Background, impacts, interim compensation and inquiry outcomes

    Between 1970 and the early 1990s, more than 30,000 NHS patients were given blood transfusions, or treatments which used blood products, contaminated with hepatitis C or HIV. Over 3,000 people have died as a result, and thousands live with ongoing health conditions. The infected blood inquiry has reported, calling for a range of measures, including immediate compensation, public memorials, and for lessons to be learned in medicine, government and the civil service.

    Infected blood scandal: Background, impacts, interim compensation and inquiry outcomes
  • Eating less sugar: Reformulating food and drink products and government policy

    Too much sugar in diets can contribute to health issues. Reformulating products, or changing how much sugar is in what people normally eat and drink, means the public do not have to change their habits to eat more healthily. Recent governments have introduced measures to decrease the public’s consumption of sugar, as well as salt and fat. However, some organisations have encouraged the government to go further by creating more mandatory schemes and levies for industry.

    Eating less sugar: Reformulating food and drink products and government policy